Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJOG8715L: Osimertinib With or Without Bevacizumab in EGFR T790M-Positive Lung Adenocarcinoma
jRCTs051180183Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Osimertinib monotherapy with Osimertinib plus bevacizumab (2 arms). Primary endpoints: Phase I safety and Progression-free survival. Started Feb 2017; status: completed.
02
Drugs
osimertinibbevacizumab
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCTs051180183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180183.